Clinical trial

Relative Bioavailability Study of HNC364 Injectable Suspension

NCT06798519

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2026-05-08

PhasePHASE1

Study timeline

Study start (actual)2026-05-08Date precision: day

Registry last updated2026-06-02

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Parkinson's Disease (PD)unresolved

Interventions

HNC364 Injectable SuspensionDRUG

Rasagiline TabletsDRUG

Sponsors & collaborators

Guangzhou Henovcom Bioscience Co. Ltd.lead sponsor

Frontage Clinical Services, Inc.collaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06798519 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.